<i>AdCD40L</i> Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial

Abstract

To our knowledge, this is the first report on immunogene therapy in bladder cancer and the first using AdCD40L in vivo. Local AdCD40L gene therapy was safe, boosted immune activation, and should be further evaluated as a single or an adjuvant therapy for urothelial malignancies.